Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity

Chia Hao Kang, Chih Min Tsai, Tin Hsin Wu, Hsin Yi Wu, Mei Yung Chung, Chih Cheng Chen, Yi Chuan Huang, Shih Feng Liu, Da Ling Liao, Chen Kuang Niu, Chen Hsiang Lee, Hong Ren Yu*

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

30 引文 斯高帕斯(Scopus)

摘要

Background Ventilator-associated pneumonia (VAP) caused by Acinetobacter baumannii is increasing. It has a high mortality rate but experience in using inhaled colistin as monotherapy for VAP in children, especially pre-term infants, is limited. This study presents experiences using aerosolized colistin as monotherapy for VAP due to A. baumannii infection in pre-term infants. Methods Eight pre-term infants (gestational age 25-36 weeks) admitted to the neonatal intensive care unit (NICU) of Kaohsiung Chang Gung Memorial Hospital in Taiwan from January 2006 to December 2010 who received inhaled colistin as monotherapy for VAP due to A. baumannii infection were retrospectively evaluated. Of the isolated microorganisms, five were multi-drug resistant strains of A. baumannii (MDR-AB) but all were sensitive to colistin. All patients received inhaled colistin at a dose of 1,000,000 IU (33.4 mg) twice daily for an average of 9.1 days (range, 4-22 days). Results All pre-term infants were cured, with A. baumannii eradicated from airway secretions. There were no clinical or laboratory adverse events related to colistin use. Conclusions Aerosolized colistin may be used as monotherapy for VAP due to A. baumannii infection in pre-term infants. A larger controlled study is warranted to corroborate the findings. Pediatr Pulmonol. 2014; 49:381-388.

原文英語
頁(從 - 到)381-388
頁數8
期刊Pediatric Pulmonology
49
發行號4
DOIs
出版狀態已出版 - 04 2014

指紋

深入研究「Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity」主題。共同形成了獨特的指紋。

引用此